Children and adults have pronounced Vitamin K2 deficiency and may benefit from MK-7 supplementation

NattoPharma announces today the publication of a new study performed in collaboration with VitaK BV, the research Institute in Maastricht, Nederland. The study is now published in Food & Function, 2014,xx, 1-6

In the paper it is described that 896 blood samples have been collected from 110 healthy volunteers, 42 children and 68 adults. The samples have been used for measurements of biomarkers reflecting the vitamin K2 status in healthy volunteers by measuring the both circulating dp-ucMGP and ucOC.

From the age of 40 years the dp-uc MGP levels at baseline – before any intake of vitamin K2 - gradually increased, pointing to an increased need for vitamin K2 supplement with increasing age. Children had the highest levels of ucOC, also pointing to a vitamin K2 deficiency.

The children and adults with the most pronounced vitamin K 2 deficiency gave the highest response s to supplementation with MenaQ7.

Children and adults above the age of 40 years showed the largest vitamin K2 deficiency, and accordingly may benefit from MK-7 supplementation to improve their vitamin K2 status”, says Elke Theuwissen from VitaK, the principal investigator in the study.

This study demonstrates a general vitamin K2 deficiency in the whole population”, says Hogne Vik, CEO in NattoPharma. “Supplementation with vitamin K2 (MenaQ7) improves the status of the biomarkers correlating with a normal vitamin K2 level in the body that is especially important for bone development in children and for delaying development of osteoporosis and vascular calcification in adults from the age of 40 years”.

The study is available at:

http://pubs.rsc.org/en/content/articlelanding/2013/fo/c3fo60464k#!divAbstract

# # #

About NattoPharma

NattoPharma ASA, Norway is an international biotechnology company and exclusive supplier of MenaQ7®, the natural vitamin K2. NattoPharma has since 2007 been in an exclusive research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:
Hogne Vik
CEO
Cell phone: +47 97 53 53 26
E-mail: hogne.vik@nattopharma.com

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.